Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ILT4 in EGFR activated non-small cell lung cancer treatment

A non-small cell lung cancer and cell technology, applied in the fields of biomedicine and molecular biology, can solve problems such as low tumor response and hindering anti-tumor immunotherapy

Active Publication Date: 2021-02-02
JINAN CENTER HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, T cells in the TME are often hyporesponsive to tumors due to exhaustion or senescence, which hinders effective antitumor immunotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ILT4 in EGFR activated non-small cell lung cancer treatment
  • Application of ILT4 in EGFR activated non-small cell lung cancer treatment
  • Application of ILT4 in EGFR activated non-small cell lung cancer treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0069] 1. Materials and Methods

[0070] 1.1 Patient tumor samples

[0071] A total of 80 tumor specimens from patients with non-small cell lung cancer who underwent surgical resection in Jinan Central Hospital Affiliated to Shandong University from January 2013 to December 2019 were collected. There was no chemotherapy, radiotherapy and other treatments before operation. Among them, there were 28 cases of squamous cell carcinoma and 52 cases of adenocarcinoma, of which 38 cases had EGFR sensitive mutation and 14 cases were EGFR wild type. Patients were classified according to the UICC / AJCC NSCLC staging system (8th edition). This study was approved by the Ethics Committee of Jinan Central Hospital, and written informed consent was obtained from each patient.

[0072] 1.2 Tumor cell lines

[0073] NSCLC cell lines (PC9, HCC827, A549, H1299, H1975) and immortalized human bronchial epithelial cell line (BEAS-2B) were purchased from the Cell Resource Center of the Chinese Aca...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to View More

Abstract

The invention provides application of ILT4 in EGFR activated non-small cell lung cancer treatment, and belongs to the technical field of biomedicine and molecular biology. Researches find that ILT4 innon-small cell lung cancer cells is activated and induced by an EGFR-AKT / -ERK1 / 2 signal channel to express. ILT4 inhibits anti-tumor immunity by collecting M2-like TAMs and weakening T cell functions, and ILT4 blocking reverses tumor immunosuppression and occurrence development. In addition, ILT4 blocking can enhance the curative effect of a PD-L1 inhibitor on EGFR wild type NSCLC, but has no influence on EGFR mutant type NSCLC. The application determines a new mechanism of ILT4-mediated tumor progression in EGFR activated NSCLC, and provides a promising immunotherapy strategy for patients, so that the application has good practical application value.

Description

technical field [0001] The invention belongs to the technical fields of biomedicine and molecular biology, and specifically relates to the application of ILT4 in the treatment of EGFR-activated non-small cell lung cancer. Background technique [0002] The information disclosed in the Background of the Invention is only intended to increase the understanding of the general background of the invention, and is not necessarily to be taken as an acknowledgment or any form of suggestion that the information constitutes the prior art that is already known to those skilled in the art. [0003] Immune checkpoint inhibitors (ICIs) targeting the PD-1 / PD-L1 axis are milestones in anti-tumor therapy in recent years. These agents have shown promising results in a variety of solid tumors and have been established as the standard of care in the first-line treatment of advanced non-small cell lung cancer (NSCLC). However, the efficacy of ICIs remains limited, with response rates not exceedi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/7105A61K31/713A61K39/395A61K49/00A61P35/00A61P11/00
CPCA61K45/06A61K31/7105A61K31/713A61K39/395A61K49/0008A61P35/00A61P11/00A61K2300/00
Inventor 孙玉萍高爱琴王琳琳陈小徵李娟张方王淑云王婧男杨子江史闻靖
Owner JINAN CENTER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com